Literature DB >> 17628014

Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing.

Svetlana Gingis-Velitski1, Rivka Ishai-Michaeli, Israel Vlodavsky, Neta Ilan.   

Abstract

Heparanase is a mammalian endo-beta-D-glucuronidase capable of cleaving HS side chains at a limited number of sites, activity that is strongly implicated in tumor metastasis, neovascularization, inflammation, and autoimmunity. Clinically, up-regulation of heparanase mRNA and protein expression has been documented in a variety of primary human tumors, correlating with reduced postoperative survival and increased lymph node and distant metastasis, thus providing strong clinical support for the prometastatic feature of the enzyme and making it an attractive target for the development of anticancer and anti-inflammatory drugs. Screening a panel of monoclonal antibodies for their ability to inhibit heparanase enzymatic activity, we noted that one hybridoma, 6F8, exhibited the opposite effect and significantly enhanced heparanase activity. Here, we provide evidence that antibody 6F8 enhances the activity of recombinant and cellular heparanase, facilitates invasion of tumor-derived cells in vitro, and improves wound healing in a mouse punch model in vivo. These results support a role of heparanase in the course of wound healing and, moreover, suggest that monoclonal antibodies can be applied clinically for the enhancement, rather than inhibition, of certain enzymes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628014     DOI: 10.1096/fj.07-8866com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

1.  Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.

Authors:  Marina Weissmann; Gil Arvatz; Netanel Horowitz; Sari Feld; Inna Naroditsky; Yi Zhang; Mary Ng; Edward Hammond; Eviatar Nevo; Israel Vlodavsky; Neta Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

2.  Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy.

Authors:  Jun Zhang; Jianmin Yang; Xiaomei Han; Zhongsheng Zhao; Ling DU; Tong Yu; Huiju Wang
Journal:  Oncol Lett       Date:  2012-05-04       Impact factor: 2.967

3.  Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity.

Authors:  Flonia Levy-Adam; Sari Feld; Victoria Cohen-Kaplan; Anna Shteingauz; Miriam Gross; Gil Arvatz; Inna Naroditsky; Neta Ilan; Ilana Doweck; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

4.  Heparanase Inhibitors Facilitate the Assembly of the Basement Membrane in Artificial Skin.

Authors:  Makoto Tsunenaga
Journal:  Curr Tissue Eng       Date:  2016-08

5.  Elucidating the Consequences of Heparan Sulfate Binding by Heparanase 2.

Authors:  Miriam Gross-Cohen; Sari Feld; Gil Arvatz; Neta Ilan; Israel Vlodavsky
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

6.  Clinical significance of heparanase splice variant (t5) in renal cell carcinoma: evaluation by a novel t5-specific monoclonal antibody.

Authors:  Uri Barash; Gil Arvatz; Roy Farfara; Inna Naroditsky; Ilana Doweck; Sari Feld; Ofer Ben-Izhak; Neta Ilan; Ofer Nativ; Israel Vlodavsky
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.